HUM-MOLGEN events: Creating Value for Licensing Deals

HUM-MOLGEN -> Events -> Meetings and Conferences

September 12, 2003

Cambridge Healthtech Institute, Park Hyatt Philadelphia, Philadelphia, Pennsylvania
October 20-21, 2003

· SPECIAL SESSION | How a Pharmaceutical Company
Differentiates Itself as the Ideal Partner
presented by Novartis, Bristol-Myers Squibb and Genzyme

· Planning and Developing Confidential Scientific Packages
that Maximize the Opportunity for Success

· Can Licensing Strategies Alter the High Rate of Failure
for New Chemical Entities?

· Better Manage Scenarios Where Multiple Potential Partners
Bid For An Opportunity

· Learn How Pharma Companies Are Becoming is More Flexible
in Structuring Licensing Deals

· Hear Successes and Failures of Recent Deals - The Good,
The Bad, & The Ugly

· NEW INTERACTIVE PANEL | Late Stage Compounds versus
Early Stage Compounds: Which Make a Better Investment?
featuring Aventis, Wyeth and Solvay

Organized by:

Cambridge Healthtech Institute

Deadline for Abstracts:

Registration:

To register visit: www.healthtech.com/2003/mtc/reg.as por call 617-630-1300.

E-mail:

chi@healthtech.com

Posted by:

Lisa Cardinale

Host:

wks140.healthtech.com

home

genetic news

bioinformatics

biotechnology

literature

journals

ethics

positions

events

sitemap